We value our partnerships with the media and welcome any inquiries about the ACG Group. Please use the resources on this page, or if you have any specific queries please reach out to the media contact listed below.
ACG launches DryPod™ – A Breakthrough Desiccant-Based Cold-Form Laminate Delivering Superior Protection for Moisture-Sensitive Pharmaceutical Blisters at PMEC 2025
ACG, the world’s most integrated provider of solid-dosage and packaging solutions, today announced the launch of DryPod™, a next-generation desiccant-based cold-form laminate engineered to protect highly moisture-sensitive drug molecules. DryPod™ marks a major advancement for pharmaceutical manufacturers who have long grappled with limited availability, rigid technologies, and compatibility issues within existing desiccant cold-form solutions.Moisture protection is essential to ensure drug potency throughout the product’s retail life. However, current market offerings rely heavily on a single patented co-extrusion-based technology, creating challenges such as restricted machine compatibility, dependence on specific lidding foils, long lead times, limited supplier options, and inconsistent on-ground technical support. DryPod™ overcomes these barriers, giving pharmaceutical companies the freedom to innovate without compromising product protection, regulatory compliance, or operational efficiency.Unlike legacy co-extruded structures, DryPod™ is built using a proprietary lamination-based approach, enabling consistent performance across all standard blister-forming technologies. This eliminates the need for specialised retrofits or process changes and gives manufacturers complete flexibility to run DryPod™ on their existing blister lines. The laminate can also be sealed with any PE-sealable lidding foil, reducing procurement dependencies and ensuring supply-chain agility across global operations.A significant differentiator for DryPod™ is its patent-clean design. Engineered with zero overlap with existing active patents in the desiccant co-extrusion space, DryPod™ offers pharmaceutical companies complete legal clarity and peace of mind when switching suppliers, scaling production, or expanding into new markets. This removes a longstanding barrier for companies seeking secure, long-term, and globally compliant moisture-protection solutions.DryPod™ is supported by ACG’s extensive global technical service network, ensuring smooth onboarding, rapid troubleshooting, and optimised packaging performance across diverse manufacturing environments. With its advanced protection capabilities and universal compatibility, DryPod™ represents a future-ready solution for safeguarding highly moisture-sensitive molecules.“DryPod™ is built for the realities of modern pharmaceutical manufacturing,” said Dr. Akbar Ali, General Manager and Head of Development and Technologies at ACG. “Manufacturers working with moisture-sensitive molecules have faced years of constraints due to rigid technologies and supply limitations. DryPod™ directly addresses these challenges, empowering innovators to bring critical therapies to market more efficiently and reliably.”With this launch, ACG strengthens its commitment to making global pharmaceutical manufacturing safer, smarter, and more flexible. DryPod™ is now commercially available worldwide.About ACGFor over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better. As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards. Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team: madhurima.chakraborty@acg-world.com
Read more
ACG wins Red Dot Design Award for Personalised Medicine Concept
ACG, the world’s most integrated provider of solid-dosage solutions, is proud to announce that its Personalised Medicine Concept (PMC) has been awarded the prestigious Red Dot Award for high design quality in the Medical Devices and Technology category. The Red Dot is an internationally recognised symbol of design excellence, awarded only to concepts that demonstrate exceptional creativity and innovation.The PMC reflects the strength of the OneACG ecosystem, bringing together expertise from ACG Capsules, ACG Engineering, ACG’s global research and development centres (Scitech India and Europe), and Vantage Nutrition, an ACG group company. This collaboration unites cutting-edge capabilities in capsule and beadlet technology, precision engineering, and digital systems to deliver a fully integrated, intelligent OSD (oral solid dosage) manufacturing solution - from development through to delivery.The Personalised Medicine Concept represents a groundbreaking advancement in personalised nutrition and medicine. By addressing the limitations of the traditional one-size-fits-all approach, the PMC enables the production of tailor-made capsules. Each batch features a unique combination and dosage of ingredients, ensuring precision, safety, and efficacy-while minimising the risks of over or under-dosing typically associated with generic prescriptions.Developed independently by ACG’s R&D teams, the PMC underwent extensive prototyping and validation. Select partners were invited to experience the technology first-hand, following which ACG entered an exclusive collaboration with Art of You (AOY) for the European market. This partnership brings together ACG’s engineering excellence with AOY’s pioneering approach to personalised supplement development.Karan Singh, Managing Director at ACG, said: “We are honoured to receive the Red Dot recognition. In the healthcare sector, everyone talks about personalisation. Few can manufacture it. That’s what makes this moment different. Our engineers, scientists, and nutrition experts have built an end‑to‑end capsule platform that can read a person’s health profile and deliver the exact combination and dose – reliably and at scale. Red Dot recognises the design quality; I am proud of ACG’s discipline and grit in making personalisation a reality”Pablo Smolders, Founder at Art of You, added “We’re proud to collaborate with ACG in bringing the PMC to life - setting a new benchmark for fully personalised, capsule-based supplements across Europe. This achievement highlights the incredible dedication and innovation that went into developing a pharmacy-grade machine designed specifically for personalised health and wellness.”Werner Bongers, CEO of Scitech, concluded “The PMC is a testament to what OneACG stands for- seamless collaboration, smart integration, and a shared vision for the future of health. As ACG’s R&D centre, Scitech leads innovation from concept to creation, and this award reinforces our belief that purposeful design can transform the future of personalised medicine.”About ACGFor 65 years, ACG has been innovating production solutions for pharmaceutical and nutraceutical companies that help make people better. As the world’s most integrated provider of oral-dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions, all fully compliant with international standards. Today, ACG partners with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everyone we serve.Media contact:ACG Media Relations - madhurima.chakraborty@acg-world.com
Read more
ACG to invest $200 million in U.S. hard-shell capsule manufacturing
Dedicated facilities for gelatin and HPMC; 200+ jobs; operations targeted for early 2027; expands ACG’s 25-year U.S. presenceACG, the world’s most integrated provider of solid-dosage solutions, today announced a $200 million phased investment to establish its first empty-capsule manufacturing operations in the United States. The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta, Georgia, with a second phase of $100 million planned to expand capacity and capabilities in the region. The investment is expected to create more than 200 jobs, with operations targeted to begin in early 2027.“ACG has served North America for over 25 years. This facility strengthens our ties with customers across the region—bringing us closer to them, enabling faster lead times, higher-quality service, and a more resilient, de-risked supply chain. Just as importantly, it lets us respond more quickly and co-develop new innovations through tighter R&D partnerships. It’s been a long time coming, and we’re glad to say it’s here,” said Karan Singh, Managing Director, ACG.ACG will establish dedicated facilities to manufacture gelatin and vegetarian (HPMC) hard-shell capsules, designed and operated to the highest global standards of quality, safety, and regulatory compliance. The program advances ACG’s Make it Better commitment and complements the company’s U.S. ecosystem spanning capsules, barrier packaging materials, processing and encapsulation machinery, visual inspection, and traceability solutions—supported by nationwide sales and service.“Atlanta is the right location to execute at scale,” said Selwyn Noronha, CEO, ACG Capsules. “Georgia and the City of Atlanta offer a pro-business environment, a strong talent pipeline, world-class connectivity, and reliable infrastructure. Combined with ACG’s recent facility builds in Aurangabad (HPMC), Thailand (gelatin), and expansions in Brazil, Croatia and India, we have the operating discipline to begin production quickly and deliver reliable supply for North American customers.”ACG has operated in the United States for more than 25 years, with North American headquarters in Piscataway, N.J., manufacturing liquid fill capsules in Chadds Ford, Pa., with several warehouses across the United States, and sales and service teams nationwide.About ACGFor 65 years, ACG has been innovating production solutions for pharmaceutical and nutraceutical companies that help make people better. As the world’s most integrated provider of oral-dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions, all fully compliant with international standards. Today, ACG partners with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everyone we serve.
Read more
Exclusive: ACG welcomes EC decision on titanium dioxide in pharmaceuticals
ACG, the world’s largest integrated supplier of pharmaceutical capsules and allied solutions, welcomes the European Commission’s recent announcement allowing the continued use of titanium dioxide in medicinal products.ACG has been deeply involved with this matter since the very inception of the concern, working on two fronts.On one side, the company has invested in the development of TiO2-free alternatives to support customer needs.On the other, ACG has played a key role in educating the global pharmaceutical community about the scientific possibilities and limitations in addressing the challenge.ACG is proud to have actively co-operated with the IQ Consortium, comprising 21 multinational pharmaceutical companies, in the creation of a robust database on the potential impact of a ban on TiO₂ in medicines.This scientific body of evidence played a vital role in informing the European Commission’s decision-making process.“This is a wise and pragmatic decision for the pharmaceutical sector,” said Dr Subhashis Chakraborty, General Manager, Head, Global Product Management at ACG Capsules.“And as the ongoing ban remains in place for the nutraceutical industry, we remain fully committed to supporting through innovative TiO₂-free capsule solutions.”Talking exclusively to NBR, Dr Subhashis Chakraborty (pictured) added: When the regulation on TiO₂ was first announced, it created significant uncertainty across the industry.ACG responded swiftly and responsibly, taking the time to understand the challenge in depth. Rather than taking advantage of the situation, we chose to proactively share the technical limitations and complexities associated with finding viable TiO₂-free alternatives.We made it very clear to our customers that an exact replacement for TiO₂, particularly to achieve white colour options, would not be possible with the current material science."This helped to set realistic expectations and prevent unnecessary reformulation risks."Our transparent communication enabled pharmaceutical companies, including the IQ Consortium, to make informed and strategic decisions, rather than operating in the dark.In doing so, we represented ourselves not only as market leaders but also as thought leaders, guiding the industry with expertise and insight, rather than simply responding to regulatory changes.In addition, while the regulatory changes originated in Europe, ACG also emphasised the broader global implications, especially for multinational corporations.We advised that organisations with global operations should remain aligned and proactively plan for potential ripple effects beyond the EU.As part of our commitment to supporting the industry, ACG has hosted multiple global knowledge-sharing sessions, including webinars, technical roundtables and direct consultations.These efforts continue to guide and educate the pharmaceutical community on both the regulatory landscape and the path forward for TiO₂-free innovations.
Read more
India's Basketball Revolution Begins: ACG launches India's First Professional Basketball League in association with BFI
Mumbai, June 6, 2025: Marking a transformative moment for Indian sports, ACG Sports Private Limited, has announced the launch of India’s first professional basketball league in association with the Basketball Federation of India (BFI). This groundbreaking initiative will feature structured competitive league in 5x5 and 3x3 formats for both men and women, establishing a comprehensive professional ecosystem that opens the door for athletes across the country to pursue basketball as a viable career.Designed to redefine how the sport is played, experienced, and supported in India, the league aims to shift basketball from a niche discipline into a mainstream pursuit. It will serve as a long-term catalyst for India’s presence on the global basketball stage, backed by world-class infrastructure, holistic athlete development, and robust community engagement.The league is being driven by ACG Sports Pvt. Ltd., a division of ACG, a global leader in integrated manufacturing solutions for the pharmaceutical and nutraceutical industries. Leveraging ACG’s deep-rooted commitment to societal advancement, this initiative represents a natural extension of its decade-long investment in grassroots basketball programs.To guide the league’s global strategy and operations, Mr. Jeremy Loeliger, Former CEO & Commissioner of Australia’s National Basketball League (NBL), has been appointed Director of ACG Sports. In his new role, Loeliger will lead the development of the league’s blueprint, bringing international standards of governance, competition, and commercial innovation to the Indian shores.“Basketball represents more than just a sport – it is a vehicle for building character, leadership, and opportunity," said Mr. Karan Singh, Managing Director of ACG. "Our decade-long journey, beginning with grassroots initiatives has focused on systematically making basketball accessible across India while building the professional pathways that young athletes need to thrive."He further added, "Our vision for this professional basketball league is to establish a self-sustaining ecosystem where every child with passion and talent can see a viable future in basketball in India. We're grateful for the partnership with BFI in making this dream a reality. While this is a commendable first step, we know that building a thriving basketball ecosystem will require sustained effort and collective support to reach its full potential.”ACG’s leadership role in this initiative goes far beyond league operations. As part of its long-term strategy, ACG will launch India’s first fully residential high-performance centre within the year. The academy will feature world-class facilities, attract top coaching talent from the U.S. and Australia, and offer comprehensive training programmes for players, coaches, and referees. Nutrition, mental wellness, and academic balance will be integral to the curriculum – ensuring holistic development of future stars.Mr. Aadhav Arjuna, President of the Basketball Federation of India, stated: “This partnership with ACG is unlike anything we’ve seen before. It is driven by vision, structured for long-term impact, and rooted in a clear understanding of what Indian basketball truly needs. We’re building not just visibility, but real momentum and global credibility. Our vision is to win medals at the Asian Games and Olympics”Mr. Kulvinder Singh Gill, Secretary General of the Basketball Federation of India, stated: “This league will unlock new opportunities for young Indian talent to grow, compete professionally, and gain invaluable exposure alongside international players and coaches.”The complete league framework including team structures, competition formats, player eligibility, and governance models – is currently in development with input from global basketball experts and key industry stakeholders. Detailed announcements on participation guidelines, venue requirements, and operational protocols will follow in a phased rollout.In the coming months, the newly formed League Council will begin overseeing standards and operations, while nationwide scouting initiatives, customised athlete development tracks, and dynamic fan engagement programs will begin laying the foundation for a vibrant, inclusive, and commercially sustainable basketball culture in India.About Basketball Federation of India (BFI)The Basketball Federation of India (BFI) is the governing and controlling body of basketball in India. It is responsible for the development and promotion of the sports at all levels. BFI manages all the national-level basketball operations in India.First national level tournaments were organized in India in 1934. The India national basketball team became a member of FIBA in 1936. The governing body, BFI, was formed in 1950. Mr. Aadhav Arjuna is the President of Basketball Federation of India.About ACGFor over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents.Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve.ACG Sports Private Limited is a wholly owned subsidiary of ACG, and while it operates in a different sector, it is firmly grounded in the same institutional principles of precision, scalability, and long-term value creation.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Packaging Materials GHG Commitment Validated and Approved by SBTi
ACG Packaging Materials, a leading global supplier of integrated manufacturing solutions for the pharmaceutical and nutraceutical industries, has taken a significant step forward in its sustainability journey as the Science Based Targets initiative (SBTi) officially validated the company’s greenhouse gas (GHG) emission reduction targets. This validation aligns with ACG’s core philosophy of Making it Better, reinforcing its commitment to impactful progress toward a sustainable future.ACG Packaging Materials has committed to reducing absolute Scope 1 and 2 GHG emissions by 90%. The company has also committed to reducing Scope 3 GHG emissions from purchased goods and services, fuel and energy-related activities, and upstream transportation and distribution by 97% per tonne of products produced within the same timeframe.Speaking on this milestone, Karan Singh, Managing Director of ACG, said, “At ACG, we recognise that the future of the pharmaceutical and nutraceutical industries depends on our ability to innovate responsibly and operate sustainably. This validation provides us with a clear, science-backed framework to drive meaningful progress in reducing our environmental impact. As we move forward, our focus will be on integrating sustainable practices across our operations, investing in advanced technologies, and collaborating with stakeholders to build a resilient, low-carbon future. This milestone is a testament to our dedication to making it better while ensuring that our industry remains aligned with global climate goals”Mr. Shivshankar S.R, CEO of ACG Packaging Materials, “The SBTi validation solidifies our commitment to a business model that thrives in a carbon-conscious future. We're not simply aiming for incremental improvements; we're undertaking a fundamental shift in how we operate. Our ambitious interim targets—reducing absolute Scope 1 and 2 emissions by 54.6% and Scope 3 emissions by 61.07% per tonne of products by FY2033—demonstrate our dedication to tangible progress. This commitment enhances our ability to attract sustainability-focused investors, fortifies our supply chain, and establishes ACG as a leader in responsible manufacturing”Sunil Kumar, Head of CSR and Sustainability at ACG said, “This validation is a testament to our unwavering commitment to environmental stewardship and social responsibility. At ACG, we believe that business success is intrinsically linked to the well-being of our planet and communities. Our focus now is on expanding our sustainability initiatives beyond our operations, engaging our employees, and partnering with local communities to create a lasting positive impact. We are dedicated to building a more sustainable and equitable future for all”The Science Based Targets initiative (SBTi), a collaboration between the Carbon Disclosure Project (CDP), United Nations Global Compact (UNGC), World Resources Institute (WRI), and Worldwide Fund (WWF), provides a globally recognized framework for companies to set GHG reduction targets aligned with climate science. It specifies how much and how quickly emissions must be reduced to limit global warming to well below 1.5°C above pre-industrial levels.
Read more
ACG to boost Mexico presence with appointment of Jessica Alfaro
ACG Engineering, a division of ACG, the world's only integrated pharmaceutical solutions and manufacturing company, is delighted to announce the appointment of Jessica Alfaro as territory sales manager for the Mexico region, as the company seeks to vastly increase its presence in the territory. In her new role, Jessica Alfaro will be responsible for promoting ACG’s portfolio of process and packaging machinery in Mexico, establishing new bonds with customers through the commitment of providing integral solutions to improve their processes. With a passion for engineering, Jessica previously worked as a sales engineer for Nicolás, Sven, Pacheco Y Andresen, Design and Engineering. Her responsibilities included the monitoring of technical specifications and industry standards, as well as the continuous development of the overall product offering. She also led board sessions, assigning requirements to valid use cases that highlighted the capabilities of the product. In addition, she worked closely with customers and the engineering team to determine the needs of the process and the requirements of the system. Commenting on the appointment, John Carey, vice-president of Sales at ACG Engineering, said: “We’re delighted to welcome Jessica into this pivotal new role. ACG is currently placing real focus and investment in the Mexico region for our process and packing machinery supporting both pharmaceutical and nutraceutical manufacturers with state-of-the-art technologies. We believe her experience and dedication will play a key part in building strong customer relations in the area.”Jessica Alfaro added: “I am delighted to be joining ACG, and embracing the challenges associated with gaining a deep understanding of our clients and providing them with the best solutions to help drive their business success. “I am excited by the idea of applying my analytical skills to design efficient and sustainable processes. My chemical engineering background gives me the opportunity to merge my passions for problem solving and teamwork, allowing me to contribute to the development of technologies and solutions that have a positive impact on the world around us.”About ACGFor over sixty years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better. As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACHEMA 2024: ACG Engineering on a mission to collectively ‘Make it Better’ World’s largest integrated supplier to the solid dosage manufacturing industry to display wide range of engineering and capsules products
At ACHEMA 2024 ACG Engineering, which provides end-to-end pharmaceutical engineering solutions,will be displaying its broadest range of products to date – underlining its commitment to ‘Making it Better’ for the industry and patients alike.The all-encompassing machines displayed will include the QUEST FB I, which is a highly versatile 'plug and play' fluid-bed unit for lab-scale feasibility studies. Also on show will be the ZRO 90T - a high-yield capsule filler. As will be the ACCURA 100FF - ACG's precision capsule checkweigher, suited for medium to large production batches with a capacity of 100,000 capsules per hour. Also on display will be the PROTAB 300 – a single rotary tablet press, which is suitable for R&D, small and medium-batch production, making scalability far easier, and the SECURECOAT TC III tablet coater, designed with operator safety and for use with highly potent active pharmaceutical ingredients (HPAPIs).Borja Guerra, vice president of international sales at ACG Engineering, said: “At ACG, we deliver efficient cutting-edge technology and a highly consistent ROI ratio for our global customer base, because we actively listen to them and their needs and take a collective approach towards ‘Making it Better’.“By aligning our shared strength and cross-divisional synergies with our Capsule and Films and Foils business units we are able to offer a whole world of different and highly targeted products and services – supporting large pharmaceutical companies and generic manufacturers with equal focus.”“We are really looking forward to ACHEMA 20024 and meeting with the industry to share knowledge and insights and to hopefully forge some new and exciting partnerships, continuing the expansion of ACG’s global footprint.”ACG will be exhibiting on stand A71 in Hall 3.1, between 10-14 June in Frankfurt.-Ends-About ACG For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents.Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
Vantage Nutrition to champion ‘better delivery’ at Vitafoods Europe 2024
At this year’s Vitafoods Europe, Vantage Nutrition (an ACG group company), will be showcasing and championing the term ‘better delivery’. With a real focus on innovation, the team will be debuting the outstanding beadlet technology, a complete product offering ultimate ingredient performance.Other ACG Capsules products on show will include ACGcaps™ H+, the world's first independently certified* ‘Clean Label' eco-friendly capsule, which is made using thermogelation technology (water and cellulose only). Alongside will be the ACGcaps™ TSafe opaque and TiO2-free clean capsules, with the enhanced version offering flexibility with pigmentation options.Aaron Quinn, head of business development at Vantage Nutrition – Europe, commented: “We know that the world’s healthiest products demand the world’s cleanest capsules performance through more advanced technologies. Through our innovations, we are committed to supporting nutraceutical brands when it comes to time consuming and costly R&D.“With the development of beadlet technology we are able to offer ultimate ingredient performance and enhanced delivery. Beadlets release ingredients over time, boost absorption and improve bioavailability. And by working with one supplier, manufacturers can ensure they have full control over all processes, with the 360 service – ensuring better results and enhanced uptake.”ACG is the world’s largest integrated supplier of pharmaceutical and nutraceutical solid dosage products and services. Along with the commitment to delivering integrated solutions and cutting-edge technology, Vantage Nutrition aims to provide the most comprehensive and advanced multiphase solutions to customers globally. The team’s focus in on turning product ideas into reality fast – helping companies enable, enhance, and differentiate nutra brands - from a full-service partnership to specific value additions.ACG will be exhibiting on stand H37, between 14-16 May in Geneva.* Certifications are applicable to certain colours and/or variants.About ACG For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents.Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Becomes the World’s First Capsule Manufacturing Factory to Join the Global Lighthouse Network Community 2023-24
ACG Capsules Pithampur, India is ACG’s 1st lighthouse to join the community Karan Singh, Managing Director and Balajikasiram Sundararajan, Chief Digital Officer attend the Global Light House Network ceremony in Davos to collect the award. ACG, the world's largest integrated supplier and service provider to pharmaceutical industry celebrated the inclusion of its capsule manufacturing facility in Pithampur, India, into the esteemed Global Lighthouse Network (GLN) by the World Economic Forum at the 54th Annual Davos Summit. The World Economic Forum’s Global Lighthouse Network has acknowledged the exemplary integration of Fourth Industrial Revolution (4IR) technologies, including artificial intelligence and big data analytics, by select factories globally. These facilities have been distinguished for their commitment to enhancing efficiency, fostering sustainable development, and simultaneously advancing their workforce’s skills and safeguarding the environment.Upon receiving the award, Mr. Karan Singh, Managing Director, said: “I am delighted to receive this recognition on behalf of my team. For me the most unforgettable part of our journey wasn't any technology or efficiency milestone, but the incredible team that made it all possible. Just ordinary people, united towards one goal, bringing about innovative collaborations to push boundaries of what is possible.” He added: “One of the stand-out features of our application was the Gen-AI integration. Something that was done in the less than two weeks. In between all the debate on what Gen-AI can do to humans it is a beautiful reminder that ‘technology is brilliant, but humans drive the change’. Let's remember that!”ACG operates across 138 countries in six continents and has positioned itself as a leader in the pharmaceutical sector by focusing on high-quality capsule production, increasing responsiveness, improving production yields, and boosting workforce efficiency. The company produces billions of capsules annually and has implemented over 25 innovative applications of 4IR technologies, including the industrial internet of things (IIoT), machine learning (ML), deep learning (DL), digital twins, extended reality, and generative AI.Selwyn Noronha, CEO, ACG Capsules, added: “We are extremely proud of our first factory lighthouse. From its inception the facility has pioneered in its field, but this latest honour recognises the excellence in adopting AI at speed and scale.“Our continued future-focused approach sets new benchmarks in quality and innovation, with the aim of ensuring maximum benefit for customers, regulators and the entire pharmaceutical ecosystem.”About Global Lighthouse Network Global Lighthouse Network is a collaborative platform bringing together forward-thinking manufacturers leading the charge in adopting Fourth Industrial Revolution technologies. Leveraging innovations like artificial intelligence, 3D-printing, and big data analytics, Lighthouses drive efficiency, competitiveness, and transformative business models at scale, fostering economic growth while championing workforce augmentation, environmental protection and providing a collaborative learning journey for all-sized manufacturers globally. The Global Lighthouse Network is a World Economic Forum initiative co-founded with McKinsey & Company and counselled by an Advisory Board of industry leaders, including Contemporary Amperex Technology (CATL), Foxconn Industrial Internet, Henkel, Johnson & Johnson, Koç Holdings, Schneider Electric, and Siemens. Factories and value chains that join the network are designated by an independent panel of experts.About ACG For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better. As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards. Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
Interphex 2024: ‘ACG focuses on lowering manufacturer’s TCO’
At this year’s Interphex, ACG Engineering, part of ACG - the world's only integrated pharmaceutical solutions and manufacturing company - will be focusing on its cost-effective approach to taking generics to market.ACG’s methodology is based on speed-to-market, production efficiency and reducing manufacturing costs.Borja Guerra, vice-president of international sales at ACG, said: “As a highly experienced global supplier of process and packaging machinery of all oral solid dosage requirements, we are attuned to local market requirements. We aim to provide a low TCO (total cost of ownership) for premium pharmaceutical equipment.“With over six decades of experience partnering in the oral solid dosage space, we have taken over 8000 generics to market, working with more than 1000 pharmaceutical manufacturers to achieve this.”ACG will be showcasing its ACCURA 100 FF. The capsule checkweigher is designed specifically for precise, automatic, and continuous weighing of each capsule – whether empty, filled or partially filled, with anything from powder to pellets, and which is format free.ACG is the world’s largest integrated supplier of pharmaceutical and nutraceutical solid dosage products and services. The company will be exhibiting on stand 3515 between 16-18 April in New York.About ACG For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents.Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year
ACG, the world’s largest integrated supplier and service provider to the pharmaceutical industry, is delighted to announce that for the fourth consecutive year, it has achieved the ‘Great Place To Work’ certification. This certification recognises employers who create an outstanding employee experience.Within ACG, five business units (Capsules, Corporate, Scitech – Research and Development Centre, Machinery, and Inspection), have been certified as a ‘Great Place to Work’. The comprehensive study, spanning five locations in India, encompassed approximately 3000 associates across management and plant categories. The process entailed a thorough survey based on key levers that define an organization's culture.Nikita Panchal, Group Head Talent, OD and DEI at ACG, said: “Winning this award for the fourth consecutive year fills me with pride and gratitude, recognizing the collective effort of our associates. It serves as a reminder of our commitment to excellence and the fact that institution-building is at the centre of all our actions as an organization.“ACG fosters collaboration by nurturing teamwork and effective communication. We care for our associates and the business community through support initiatives, and we remain progressive by supporting change and innovation. Our associates are encouraged to embrace our values, seize opportunities for growth and contribute their unique talents to shape a bright future together.”Sunil Jha, Group CHRO of ACG Group, added: “ACG thrives on collaboration through cross-functional teamwork, and – at all times – we prioritize the wellbeing of our associates.“Winning this award is incredibly gratifying and I am appreciative that all our associates have worked together to make this happen.”-Ends-About ACGFor over sixty years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better. As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Inspection launches new cloud-based offering to address upcoming VRS requirements under DSCSA regulations
In light of the impending Drug Supply Chain Security Act (DSCSA) regulations, ACG Inspection, a leading track and trace solutions provider for the pharmaceutical industry, has launched its new cloud-based Verification Router Service (VRS).The new system, which forms part of the ACG’s Inspections Life Sciences Cloud Service and Compliance Gateway, enables the automatic verification of saleable returns through product identifiers by routing requests and responses between stakeholders. Serialized products are assigned a unique identifier that can be used to track the product throughout its entire journey, enabling wholesalers to verify the authenticity of the products before they are resold.Shine Vijayan, CTO at ACG, commented: “The regulations, which have now been delayed by 12 months (coming into force in November 2024), will require all trading partners in the pharmaceutical supply chain to verify the identifier of any serialized drug product before redistributing it.“ACG’s existing VeriShield solutions tackles the implementation and interoperability challenges faced at Level 1, through to Level 3. With DSCSA’s regulation in place, ACG’s VRS covers level 4 - helping pharmaceutical manufacturers, distributors and retailers easily track and verify the saleable returns and secure their supply chain from counterfeit and substandard products.“ACG works closely with its customers, helping to address their pain points - one of which being concerns around data security. Our VRS employs robust security measures to safeguard serialized product information, guaranteeing the confidentiality and integrity of sensitive data throughout the verification process.”The system also guarantees real-time verification, to enhance operational efficiency and prevent supply chain delays. Additionally, it provides scalability assurance to accommodate an expanding volume of serialized data, to ensure continued robustness and reliability. And it incorporates exception handling, empowering stakeholders to address issues promptly to help maintain supply chain integrity.Shine Vijayan: “We are trusted experts and through our Life Sciences Cloud Service and Compliance Gateway, we can support counterfeit prevention, improving recall efficiency and data security. At all times, ensuring our clients are fully compliant with international standards and ready to meet the requirements as laid out in the impending DSCSA regulations.” -Ends- About ACGFor over sixty years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better. As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Engineering launches the Smart Coater X.ONE Series Company’s fastest tablet coater ensures optimised production processes
ACG Engineering, a division of ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is delighted to launch its new Smart Coater X.ONE series, the company’s fastest tablet coater to date.The Smart Coater X.ONE has been designed to make tablet coating extremely fast, with an extra emphasis on process speed, efficiency and operator ease. Its advanced baffle design ensures the quickest process times for batches from 10-100%.Features of the new coater include a unique airflow pattern for optimized drying, a fully-perforated coating drum, closed dust-free charging, integrated discharge baffles, temperature sensor, a high-performing spray-arm and a 2.0 spray nozzle which has been developed with an anti-bearding cap. It also incorporates ACG’s exclusive X•ONE command and control system, designed to facilitate compliance with cGMP standards. Richard Stedman, CEO at ACG Engineering, said: “Our Smart Coater machines are already renowned for their innovative features and operator friendly designs. Now, after a lengthy period of development, we are excited to announce the launch of the X.ONE series.“Our quality-commitment philosophy means that the new machine has been crafted to achieve maximimum efficiency and flexibility for superior tablet coating, across every process – from charging to coating, discharging to cleaning. Each and every cycle is now swifter, more streamlined and profitable.“The fast tablet coater to date is already garnering real interest, and we look forward to continuing to showcase it capabilities at the upcoming CPhI event in Barcelona at the end of the month.” (XXX – may want to adapt this sentence, to reflect true accuracy)-Ends-About ACGFor over 60 years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG acquires Technical Aluminium Foil Company
Further underpinning business growth across the Middle Eastern and African marketsACG announces full shareholding ownership of Technical Aluminium Foil Company (TAFC). This strategic move further solidifies ACG's growth trajectory across the Middle Eastern and African markets.As the world's only integrated pharma manufacturing solutions company, ACG offers a diverse range of products including capsules, films, foils, engineering equipment and inspection systems. The addition of TAFC, a prominent aluminium foil packaging company based in the UAE, strengthens ACG's position as a leading provider of comprehensive packaging solutions.TAFC boasts over a decade of experience serving the pharmaceutical and food industries with its extensive range of aluminium and specialty packaging foils renowned for their exceptional high barrier properties. The company's expertise in lacquering, lamination, printing and slitting further enhances ACG’s capabilities in meeting the diverse packaging needs of its clients.This acquisition represents ACG Group's inaugural venture in the Middle East, following recent successful acquisitions of ComboCap and AquaCap in the Americas. TAFC seamlessly aligns with ACG Films and Foils' existing business operations, enabling both entities to harness their collective strengths and expertise for accelerated growth.Shivshankar S.R., CEO at ACG Films & Foils, said: “We are excited to be making our first acquisition in the UAE. This strategic collaboration will further support our work in bringing innovative and high-quality packaging products to market, while reducing lead times and improving service levels.“By joining forces, the companies will be able to leverage their combined strengths and expertise to propel the business forward in the Middle Eastern and African markets.”-Ends-About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos. ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
Vantage Nutrition LLC acquires ComboCap Inc
This acquisition positions Vantage Nutrition as the only company in the world supplying Sidebysideä health products to nutritional and pharmaceutical markets, for enhanced combinations.Vantage Nutrition, an ACG group company announces full shareholding ownership of ComboCap Inc (USA) and BioCap (South Africa).ComboCap is renowned for the invention and commercialization of its Sidebyside technology, the world’s first three-piece capsule health product that contains an internal divider, enabling wet and dry ingredients to be brought to market side by side, separated-but-together. Backed by 80 international patent awards ComboCap has been supplying nutritional brand customers with unique finished product solutions out of its cutting-edge cGMP plant in NJ, USA. This acquisition marks a significant milestone for Vantage Nutrition and ACG, as it further expands its technology and customer solutions footprint in North America and around the world.ACG is the world’s largest integrated supplier of pharmaceutical and nutraceutical solid dosage products and services. Vantage Nutrition, an ACG group company, already has an excellent reputation as an innovator of liquid filled capsule solutions. ComboCap marks Vantage Nutrition’s second US investment in less than a year, and first in S.A, after Philadelphia-based ‘AquaCap’ was acquired from Nestlé S.A. With this expansion of manufacturing capabilities and patented technology, along with the commitment to delivering integrated solutions and cutting-edge technology, Vantage Nutrition aims to provide the most comprehensive and advanced multiphase solutions to customers globally.Karan Singh, Managing Director at ACG, said, "As one of world’s largest producers of empty hard-shell capsules, at ACG we have often thought, what next? Strengthening our portfolio of most comprehensive vegetarian and gelatin capsules, in every imaginable size, I am thrilled to announce the acquisition of ComboCap Inc and BioCap. We now will hold the patented design and specialized equipment used inproducing the world’s first 2-in-1 capsule product with a movable membrane, becoming the sole proprietor of this technology globally.With our partners, we will usher a new era in new combinations of dietary supplements, and even non-prescription or over-the counter (OTC) remedies as well as prescription (Rx) medicines to be delivered in a single dose. This technological breakthrough is a solution to current formulation challenges with many combination therapies, including incompatible ingredients or molecules. Capsules are arguably the safest and most reliable way to deliver medicine and we at ACG strive to make it better.”Tobie Louw, a Founder and CEO of ComboCap Inc, said: “Vantage Nutrition is the perfect partner for our business, and we are very excited to be part of the ACG family. We share a passion for innovation and the commitment to bring nutraceutical and pharmaceutical customers the best possible solutions and services. By joining forces and leveraging our collective capabilities we’ll no doubt bring Sidebysideä to nutraceutical and pharmaceutical markets the world over.”-Ends-About Vantage NutritionVantage Nutrition, part of the ACG Group, is one of the world’s largest and most respected manufacturer of hard-shell liquid-fill capsule solutions. As a strategic consultancy and manufacturing partner in the nutraceutical space, Vantage Nutrition helps clients bring high-quality and innovative products to market, fast. About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos. ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Engineering – SECUREFILL 40T
Tablets & CapsulesCapsule Filling Equipment & Supplies (February 2023)ACG Engineering – SECUREFILL 40TThe Securefill series is ACG’s high-level containment capsule-filling machine range. Designed for filling capsules with highly potent and/or toxic drugs, the machines comply with occupational exposure band (OEB) up to level 4.Built with operator safety in mind, these machines are equipped for filling capsules with oncological, biopharmaceutical, antiviral formulations, and other such highly potent active pharmaceutical ingredients (HPAPIs).Features:• SS316L monoblock structure containing HEPA filters, a rapid transfer port (RTP), glove ports, and accurate dosing mechanisms maintained in a negative pressure environment.• Provision for contained charging and discharging.• Wet-in-place system to ensure wetting of all suspended particles in the pharma zone.• Can be integrated with check-weighers, metal detectors and de-dusters under containment conditions.Benefits:• Ensures complete containment, thereby avoiding operator contact within OEL range 1-10µg/m3.• Integrated containment philosophy for upstream and downstream processes.• Enables easy cleaning.• Supports the production of life-saving drugs that contain HPAPIs.Technical specifications: SECUREFILL 40T Capsule size 00 - 5 Maximum speed 40,000 capsules/hour OEL 1-10µg/m3About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos. ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
Vantage Nutrition LLC acquires Aquacaps from Nestlé Health Science
Vantage Nutrition’s innovative nutraceutical offering expands into North America.. Vantage Nutrition, an ACG Group company, announced on 1st December 2022 that it has acquired Philadelphia-based ‘Aquacaps’ – an asset of Nestlé Health Science. Aquacaps is a leading contract manufacturer of liquid-filled capsules within the nutritional supplement industry in the United States. Its novel liquid delivery technology allows for the liquid filling of hard gelatin and vegetarian capsules. ACG is the world’s largest integrated supplier of pharmaceutical and nutraceutical products and services. Vantage Nutrition, an ACG group company, already has an excellent reputation as an innovator of two-piece liquid fill capsule solutions. The company’s mission is to be the most efficient partner in delivering innovative and high-quality nutraceutical products to customers globally. Karan Singh, Managing Director of ACG, said: “Although ACG has been established in North America for the last 20 years, this marks our first acquisition in the territory and is a key next step in our global expansion strategy. With this increase in our footprint and manufacturing capabilities, coupled with Vantage’s innovative technologies and 360-degree service offering, we aim to provide the most advanced combination liquid-fill solutions for customers across the region.” About VantageVantage Nutrition, part of the ACG Group, is one of the world’s largest and most respected manufacturer of hard-shell liquid-fill capsule solutions. As a strategic consultancy and manufacturing partner in the nutraceutical space, Vantage helps clients bring high-quality and innovative products to market, fast. About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos. ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG appoints Shankar Gupta as Chief Sales Officer Industry authority to re-join business in a newly created role
ACG, the world’s largest integrated pharmaceutical and nutraceutical manufacturing solutions provider, is delighted to announce that Shankar Gupta will be re-joining the business in the newly created role of Chief Sales Officer.In his new role, Shankar will be responsible for driving sales across all four ACG divisions (Films and Foils, Capsules, Inspection and Engineering) in order to continue building the company’s ‘One ACG’ agenda. Essentially, this will involve bringing further uniformity to ACG's customer outreach processes, creating more integrated solutions, and ultimately providing a consistent brand experience to ACG’s global customers, regardless of business division or location. He will also focus on scaling new initiatives.Shankar will report directly into the managing director, Karan Singh, who comments:"I am so pleased that Shankar Gupta has decided to rejoin the business during this exciting time. His understanding of ACG and its deliverables, and deep insight into our customers’ businesses will help us to align ourselves better to their changing needs. More importantly, he will champion and support better collaboration and partnership with customers.“Shankar will be pivotal in calibrating and aligning our business units to our goal of ‘Making it Better’, and our belief that everyone deserves access to good medicine."Shankar Gupta adds: “I am excited to use my experience in the pharmaceutical industry to augment ACG's growth by aligning the organisation to the changing dynamics of the global healthcare Industry.“It will certainly call for a huge collaboration of efforts both internally and with our customers, but will ultimately lead to a richer, deeper and more numerous partnerships.”-Ends-About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos. ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG appoints Udit K Singh as CEO of ACG Inspection
ACG, a leading supplier of fully integrated manufacturing solutions to the global pharmaceutical and nutraceutical industry, is pleased to announce the appointment of Mr. Udit K Singh as the new chief executive officer (CEO) of its Inspection Division.Mr. Singh will be supporting the company as it continues its growth and global expansion. He will be responsible for ensuring that every dose of medication that ACG Inspection’s pharmaceutical and nutraceutical partners provide is manufactured and delivered exactly as intended. That is down to the fact that ACG’s visual inspection systems track and monitor the manufacturing lines to guarantee flawless, safe products.Karan Singh, managing director, ACG said: “ACG is focused on building a diverse, world-class team by hiring top international talent. We are delighted to welcome Udit Singh to ACG Inspections. He has had an illustrious career and brings diverse and unique capabilities, including a robust understanding of the pharmaceutical sector.“The team looks forward to tapping into his deep experience to enrich our global work towards making the world safer and healthier. With his knowledge and expertise in this field, Udit Singh is sure to take ACG Inspection to newer heights.”Mr. Singh added, “I am pleased to join ACG and will work to ensure that our advanced serialisation, aggregation and anti-counterfeiting solutions track and protect medicines all the way through the supply chain, and into the hands of those who need them.“We are investing substantially to ensure our track and trace platform performs seamlessly and complies with regulatory requirements all over the world. I look forward to playing an integral role, and contributing towards the continued development, working with a world-class team.”About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for almost sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos, and ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Capsules launches campaign to promote problem-free pharmaceutical production
-One of the world’s largest producers of empty hard-shell capsules is on a mission to‘Love NOTHING’ when it comes to zero-problem productionACG, one of the world’s largest producers of empty hard-shell capsules, has launched its global pharmaceutical campaign: ‘ACG loves NOTHING’. The campaign is aimed at significantly improving pharmaceutical production through collaboration and industry-leading innovation. With a host of value-added services on offer, ACG has taken a pledge to strive for zero-problem pharmaceutical and nutraceutical manufacturing.Alex Robertson, CMO at ACG, said: “The messaging at the centre of this campaign is: ‘ACG loves NOTHING’ – we are putting every effort towards zero-problem production. That’s because when ‘nothing’ happens during pharmaceutical and nutraceutical production, everything runs reliably, and our customers can get the products they make to the people who need them. We will achieve this by providing the highest quality empty capsules and all the holistic advice and expertise required for seamless operations.”Founded 60 years ago, ACG was created on the simple principle of ‘Make it Better’. As the world’s largest integrated supplier of solid dosage pharmaceutical and nutraceutical products, and with the most comprehensive ranges of vegetarian and gelatin capsules globally, ACG has the scale and range to have a far-reaching impact on pharmaceutical production and human health.Selwyn Noronha, CEO ACG Capsules, added: “The pharmaceutical sector is regulated and highly competitive. Companies operating within it need a diverse range of quality capsules that help them stand out from the crowd, while also meeting demands for clean and natural products.“Beyond exceptional products, these companies need expertise and a lifetime of targeted support to ensure efficient manufacturing and guarantee regulatory compliance. With proficiency in all aspects of manufacturing from capsules to machines and protective barriers, for the last 60 years ACG has been the only company to offer this level of support, and it continues with this focus at the heart of operations.”So, at ACG, there really is something about NOTHING. The company is on a mission to drive towards problem free production and collaborating with its customers to collectively deliver on its mission of creating a healthier world.About ACGIn accordance with its commitment to making the world healthier, ACG has now been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for 60 years, across six continents and in 138 countries.‘Collaboration’ is at the core of ACG’s ethos, and ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment, and inspection systems – all that meet international regulatory requirements.For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
Capsule Manufacturing Technology: Innovations Shaping the Future
The pharmaceutical capsule manufacturing industry stands at the forefront of innovation, continuously evolving with new technologies and trends that drive efficiency, improve product quality, and address the complexities of modern medicine. The past decade has witnessed significant strides in capsule manufacturing technology. Each step has been optimized for efficiency, stability, and compliance with ever-tightening regulations. This article delves into current trends, technological advancements, and prospects in capsule manufacturing. Informed by expert opinions, it draws from interviews with industry professionals spanning the pharmaceutical capsule manufacturing landscape.Manufacturing TechnologyCapsule manufacturing technology has undergone significant transformations driven by the pursuit of enhanced efficiency, precision, and versatility. Traditional encapsulation methods, such as manual filling and sealing, have gradually given way to automated processes leveraging cutting-edge machinery and robotics. High-speed encapsulation systems with advanced dosing mechanisms and quality control features have emerged as a game-changer.These cutting-edge machines have revolutionized production workflows, allowing pharmaceutical companies to meet the rapidly escalating demand for medicines while maintaining strict product quality. With the ability to encapsulate thousands of doses per hour, these systems have increased production speed and reduced manual labor, ultimately saving time and money. Incorporating quality control features, such as automated weight checks and accuracy monitors, ensures that every dose meets the high standards of the pharmaceutical industry. These high-speed encapsulation systems have transformed pharmaceutical production, enabling companies to meet growing demand and uphold the highest product quality and safety standards.AI in ManufacturingIntegrating automation and AI into capsule production processes represents a transformative leap forward in manufacturing efficiency and productivity. ACG’s capsule manufacturing factory in Pithampur, India, was recently incorporated into the World Economic Forum’s Global Lighthouse Network. ACG’s achievement as the world’s first capsule manufacturing facility to join this prestigious network underlines the pivotal role of automation in shaping the future of pharmaceutical production. At the heart of ACG’s success lies the adoption of generative AI, a cutting-edge technology that has revolutionized standard operating procedures (SOPs) and workforce training.“Our adoption of generative AI was a key reason for ACG’s selection.” Says Anil Andrade, Vice President of Global Sales at ACG World. “The team developed and deployed an AI-driven standard operating procedure (SOP)-interfacing co-pilot. Our in-house data science team drew from 200+ quality, manufacturing, and printing SOPs, maintenance instructions, and case sheets to build a learning model in just two weeks. It was then deployed over 4-6 weeks across multiple channels using the web, mobile, and kiosks to train shop-floor personnel. Using gamification with leader boards, rewards, and recognition, the system has supported a 44% rise in workforce productivity and a 30- 40% reduction in mean time to repair, resulting in a 98% reduction in critical defects.”This shift towards automation and leveraging modern technology in capsule manufacturing enhances operational efficiency and fosters a culture of continuous improvement and innovation. By harnessing the power of AI-driven technologies, manufacturers can optimize production workflows, mitigate risks, and drive sustainable growth in an increasingly competitive market landscape.Advancements in Soft Gel TechnologyAdvancements in soft gel technology have propelled the pharmaceutical industry towards more efficient and sustainable manufacturing practices, catering to both consumer demand and regulatory standards. Soft gel capsules, characterized by their versatility and suitability for large manufacturing batches, have become increasingly popular in recent years. Nutraceuticals have also adopted the use of soft gel capsules. However, challenges such as cross-linking between the capsule shell and the fill and leaking soft gels have prompted innovation in gelatin technology to address these concerns. GELITA, a manufacturer of collagen peptides, collagen, and gelatin, has innovated a solution to this pain point.“Specific gelatin grades help to avoid cross-linking – no matter how challenging the fill is and even under difficult storage conditions, the stability and shelf life of soft gel capsules can be improved.” Says Jessica Pföhler, Global Marketing & Innovation Management – Business Unit Performance Solutions, GELITA, “We have been able to develop pharmaceutical-grade soft gel gelatin that helps manufacturers to improve soft gel seams and, thus, avoid leaking soft gels, increasing machine speed, and even reducing the ribbon thickness (less raw material use for production) and not waste raw materials – especially when it comes to expensive fills. All this leads to improved efficiency, lower production costs, and more sustainable handling of raw materials and can be achieved by changing only one parameter in the production process: the right gelatin.”Furthermore, the demand for enteric soft gel capsules, designed to dissolve in the small intestine instead of the stomach, has surged due to their ability to protect acid-sensitive ingredients and enhance consumer compliance. Traditionally, enteric capsules require a separate coating process, adding complexity and cost to production. However, with the advancements in gelatin technology, GELITA has now enabled the production of truly enteric soft gels in a single step, streamlining manufacturing processes and making enteric technology accessible to all soft gel manufacturers.Advancements in soft gel technology, driven by innovative gelatin solutions, are reshaping capsule manufacturing by enhancing stability, efficiency, and sustainability. By addressing key challenges such as cross-linking, leaking, and enteric delivery, these advancements empower manufacturers to deliver safe, compliant, and high-quality products to consumers.Trends Shaping Capsule ManufacturingConsumer demand for personalized healthcare solutions has spurred a trend toward customized capsule formulations tailored to individual patient needs. From dosage adjustments to incorporating specific active ingredients, manufacturers increasingly embrace flexibility in capsule design and composition. This trend enhances patient adherence and therapeutic outcomes and fosters brand loyalty and differentiation in a competitive market landscape.Personalized HealthcareThe expanding trend towards personalized healthcare is paralleled by the rapid evolution of nutraceutical technology, exemplified by innovations such as Sidebyside dietary supplements. Sidebyside products represent a groundbreaking advancement in oral dose capsules. Using a three-piece capsule design, Sidebyside capsules feature a unique cup-shaped divider membrane separating wet and dry ingredients or incompatible actives within the same product. This innovative design allows for simultaneous but separate housing of ingredients, ensuring optimal efficacy and compatibility. With both chambers dissolving simultaneously upon ingestion, Sidebyside supplements facilitate the coordinated release of ingredients, leading to enhanced nutrient absorption, particularly in the presence of oils. ACG’s future Sidebyside roll-out program includes features such as delayed release, catering to the growing market demand for products that provide targeted benefits at different stages of digestion. This innovative approach not only underscores the shift towards personalized healthcare solutions but also highlights the potential of nutraceutical technology to address individualized health needs effectively.Environmentally Sustainable PracticesIn response to growing environmental concerns, the pharmaceutical industry is prioritizing sustainable manufacturing practices across the entire production lifecycle, including capsule manufacturing. From eco-friendly materials sourcing to energy-efficient manufacturing processes, companies are exploring innovative solutions to minimize their carbon footprint and reduce waste generation. Biodegradable capsule materials, reusable packaging, and closed-loop manufacturing systems are among the sustainable initiatives gaining traction in the industry.Pharmaceutical manufacturing companies are increasingly embracing environmentally sustainable practices across various facets of their operations, as evidenced by initiatives from GELITA and ACG. GELITA’s innovative enteric solution for soft gels represents a more sustainable alternative to traditional enteric capsules, offering enhanced environmental benefits. Additionally, GELITA’s development of EASYSEAL gelatin contributes to sustainability by minimizing waste in soft gel manufacturing processes through the prevention of leaks and reduction of raw material usage.ACG’s commitment to sustainability is evident in its adoption of HPMC capsules, which replace animal-derived resources with cellulose, aligning with global efforts to reduce dependence on animal products. Furthermore, ACG’s focus on recyclable and compostable packaging materials underscores their dedication to environmental stewardship throughout the product lifecycle. Investments in renewable energy sources, such as solar farms, and the implementation of Zero Liquid Discharge facilities further demonstrate the industry’s commitment to minimizing environmental impact. Recognitions like the Green Dot award highlight pharmaceutical manufacturing companies’ leadership in environmental sustainability, setting a precedent for responsible and ethical practices in the industry.ConclusionThe pharmaceutical capsule industry is experiencing a transformative shift driven by innovation, sustainability, and personalized healthcare solutions. Over the past decade, advancements in manufacturing technology, including automation and AI integration, have revolutionized the capsule production process[1]es, enhancing efficiency, precision, and versatility.Moreover, the trend towards personalized healthcare has prompted the development of customized capsule formulations tailored to individual patient needs, fostering patient adherence and therapeutic outcomes. Innovations such as Sidebyside dietary supplements exemplify this trend, offering groundbreaking solutions for simultaneous but separate housing of ingredients within a single capsule. Additionally, pharmaceutical companies prioritize environmental sustainability across the entire production lifecycle, with initiatives ranging from sourcing eco-friendly materials to energy-efficient manufacturing processes.Collaborative efforts from pharmaceutical capsule technology and service providers underscore the industry’s commitment to responsible and ethical practices, setting a precedent for a more sustainable and patient-centric future in capsule manufacturing. As the pharmaceutical landscape continues to evolve, these innovations and sustainability efforts will play a pivotal role in shaping the future of capsule manufacturing, ensuring safer, more effective, and environmentally conscious pharmaceutical products for patients worldwide.Publication DetailsThis article appeared in Tablets and Capsules Magazine:Source: https://www.tabletscapsules.com/
Read more
Produto, criado pela ACG, leva de cinco a dez anos para se decompor, enquanto o…
Empresa cria PVC biodegradável para cartões e embalagens de medicamentos
A ACG Packaging Materials, empresa do setor de embalagens plásticas, desenvolveu um plástico biodegradável que se degrada em até dez anos no aterro sanitário, inovação que pode reduzir a produção de plásticos tradicionais nos setores financeiro e de saúde.A empresa, que cria embalagens e soluções para as indústrias farmacêutica e de cartões bancários, desenvolveu uma tecnologia para incluir aditivos para a produção de um PVC de rápida decomposição, chamado de Bio D. Dessa forma, quando descartado, a ação de bactérias em aterros altera a estrutura química do material, acelerando sua degradação.De acordo com o CEO da ACG Packaging Materials América Latina, Daniel Aymard, o objetivo da criação era resolver o problema da geração de resíduos na indústria farmacêutica. Os blisters, plásticos que envolvem capsulas e pílulas de medicamentos, são PVCs de vida útil curta, mas com uma decomposição que pode levar até 500 anos.“Desde os anos 1960, quando a indústria começou a desenvolver soluções para as farmacêuticas, nossa consciência sobre a preservação do meio ambiente aumentou. Por isso, buscamos uma solução mais sustentável para essa realidade”, conta o CEO.Em um aterro sanitário, explica Aymard, a temperatura pode alcançar de 25 °C a 60 °C, o que influencia no tempo de decomposição do produto: na temperatura mais baixa, o PVC levaria dez anos para se desintegrar, mas, com a temperatura máxima atingida, o plástico criado pode se degradar completamente em cinco anos. A ACG ainda garante que o produto passa a se degradar apenas nas condições de temperatura, umidade e acidez de um aterro.A preocupação durante o desenvolvimento, segundo o CEO, era que a indústria não perdesse produtividade no manuseio do material. De acordo com Aymard, a produção se assemelha ao PVC comum em todas as esferas de performance, o que pode garantir uma maior adesão da indústria ao plástico biodegradável.O custo para a produção, no entanto, é 25% mais caro que o PVC comum. De acordo com Aymard, o motivo é a produção mais longa e complexa do que o feito no plástico comum para embalagens. Para o cliente final, o custo não aumentaria. “A embalagem representa até 2% do preço do medicamento. Um aumento de 25% nessa fatia não é de grande impacto para o consumidor, seria questão de centavos de aumento”, conta.Mesmo assim, para Aymard, o produto se destaca no custo-benefício. Ele explica que a maior preocupação sobre a gestão dos resíduos beneficia a produção de produtos biodegradáveis, e que evitar a produção de plásticos duráveis ajuda a reduzir os custos com o lixo posteriormente.A expectativa é que a indústria bancária seja mais receptiva para o produto a primeiro momento. Isso porque a regulação para a produção dos cartões é mais flexível — em algumas financeiras, os cartões já são produzidos a partir de plásticos reciclados, o que pode abrir portas para a inclusão do plástico biodegradável também. Para as farmacêuticas, a preocupação é com os critérios de regulamentação das embalagens, o que ainda deve atrasar a adesão da indústria a métodos mais sustentáveis.Source: Empresa cria PVC biodegradável para cartões e embalagens de medicamentos
Read more
MD Karan Singh explains the journey in achieving the “Oscars of manufacturing”
ACG’s Moonshot Moment : becoming part of WEF’s GLN community
Last month, India’s largest capsules maker and the world’s second-largest – ACG – was feted in Davos, on joining the World Economic Forum’s Global Lighthouse network.“Lighthouses” are a beacon of sorts, when it comes to adopting advanced technologies to transform manufacturing, and globally there are 153 certified Lighthouses, across industries.ACG Managing Director Karan Singh explains their journey in achieving the “Oscars of manufacturing”. As a supplier to every other pharma company in India and major global companies – the milestone puts it in a small and elite group that is implementing advanced manufacturing technologies and boosting productivity, sustainability and supply chain resiliency - a beacon for others in the industry.Listen to the podcast at - Spotify, Apple Podcasts and Official Website.( Host: PT Jyoti Datta, Producers: Nabodita Ganguly & Siddharth Mathew Cherian)-----About the State of the Economy podcastIndia’s economy has been hailed as a bright spot amid the general gloom that seems to have enveloped the rest of the world. But several sectors continue to stutter even as others seem set to fire on all cylinders. To help you make sense of the bundle of contradictions that the country is, businessline brings you podcasts with experts ranging from finance and marketing to technology and start-ups
Read more
Multi-particulate Formulations
Multi-particulate Formulations - Tablets or Capsules?
After assessing the various routes of drug administration, oral delivery stands out as the safest and, as a result, the most universally accepted among patients. In this context, single-unit dosage forms, including tablets followed by capsules, have been identified as the preferred designs for immediate or modified release formulations. In addition, multiple-unit dosage forms, comprising of discrete particles like pellets or minitablets combined in a single dosage unit, have also gained significant popularity due to their benefits.Multi-particulate Formulations: The Power of ManyTraditionally, these multi- particulates are filled into empty hard capsules using automated capsule filling machines. However, more recent technologies have enabled the pellets to be compressed into multiple-unit pellet system (MUPS) tablets or pellet-containing tablets. Once these special tablets are exposed to the aqueous environment of the stomach, they disintegrate rapidly into individual pellets, releasing the drug like uncompressed pellets filled in capsules. MUPS technology has gained considerable acceptance, particularly in the European market, with a number of products coming to the fore, including: Beloc® ZOK (Metoprolol Succinate SR plus Hydrochlorothiazide), Antra® MUPS (Omeprazole) and Prevacid® SoluTabTM (Lansoprazole), Nexium (Esomeprazole), Galanil PR (Galantamine HBr), Lipidown (Orilistat), Esomezol (Esomperazole SR), TOP ROL XR (Metoprolol Succinate) and Cartia (Diltiazam).Since the total drug is divided equally into many units in a multiple-unit system, it demonstrates several advantages over single-unit systems. When administered orally, these particles (less than two mm in size) distribute evenly across the extensive surface area of the stomach. They behave like fluids and have a shorter retention time. Their small size also facilitates uniform gastric distribution, potentially reducing food induced variations in inter-and intra-individual bioavailability, minimizing chances of side-effects and local toxicity. MUPS tablets can also greatly reduce the risk of premature dose dumping leading to drug degradation or gastric irritation due to any failure in functional coating. This is because a failure of a few units may not be as detrimental as the failure of a single-unit system. Moreover, MUPS tablets also offer the possibility of adjusting dosage strengths, administering incompatible drugs together and combining multi-particulates with different drug-release rates to customize the release profiles.However, despite the various advantages that this unique dosage form provides, the appropriate presentation of these multiple units in the final formulation must be carefully considered. Should these pellets be filled in capsules or compressed into tablets? The best way to determine this depends on a comprehensive understanding of the overall formulation and manufacturing process of the MUPS technology.Key Variables in MUPS Tablet DevelopmentUnlike capsules, MUPS technology requires special excipients and critical process parameters to enable safe and easy compression. This ensures the pellets retain their properties, and that their drug release profile is unaffected. Some of the essential variables determining the success of MUPS tablets include:• particle size of coated pellets,• flexibility and thickness of functional coating,• type and quantity of cushioning agent, • and tablet compression forceIn capsule filling, there are no size limitations for pellets. Usually, larger pellets are preferred as they are easy to manufacture and handle. However, for MUPS, a smaller particle size of pellets is preferred as they are easy to compress and present minimal risk of pellet damage. Special excipients, also referred to as cushioning agents, are used as extra granular material for compression. Since these excipients are available in the powder state, they are often granulated to improve the particle size and density that help to ensure a homogenous distribution of the pellets in the excipient blend. It also minimises the possibility of size separation on the turret during tablet compression, thus maintaining content uniformity in the tablets.It is also important to realize that, by virtue of using smaller-dimension pellets, the resultant surface area increases exponentially as the particle size decreases. This demands higher polymer coating build up, which adds to the processing time and raw material cost. Moreover, the functional polymer coating must be flexible enough for the pellets to deform but not rupture under high compression force. This is typically addressed by using polymers that are inherently flexible or by adding the optimum amounts of plasticizers. Usually, a higher coating build up is preferred in these formulations to compensate for any slight damage without compromising the release profile. Finally, from a process perspective, the compression pressure is the most critical parameter. The mechanical properties of MUPS vary significantly from conventional tablets. Therefore, the compaction force required for pellets and powdered excipients are also very different. And the process becomes more critical if the pellets are functionally coated to modify the drug release. This requires an extremely tightly controlled manufacturing processes. For example, the range of compression force is kept narrow to ensure optimum pressure. Higher compression forces can damage the pellets, while low and inadequate compaction can result in friable tablets. The development of dedicated tablet compression machines with special turret designs and reduced vibration in recent years has helped to prevent blend segregation during operations.Despite all precautions, there remains the potential for pellet damage and the drugs being exposed to the external environment. This can sometimes manifest as minute spots on the surface, which are especially noticeable in sensitive Active Pharmaceutical Ingredients (APIs). However, in most cases, the therapeutic potency may not be significantly compromised. But, since such colour changes interfere with the aesthetics of the final formulation, an additional film coating becomes necessary to mask any possibilities of market rejections.A Prescription for the Drug Delivery DilemmaThe entire MUPS development process is a complex one. The combined impact of the raw materials along with critical process variables makes it extremely labour-intensive, time consuming and expensive. In the case of capsules, however, the absence of additional excipients, ready-made shells to fill, and a simple capsule filling process ensure far less complexity. Moreover, for scaling up or down pellet production for different strengths, capsules are much easier to handle. The absence of any extra granular powder excipients eliminates the possibility of dust generation, thus ensuring a safer and clean working environment. From a patient perspective, capsules also cater to pediatric and geriatric patients with swallowing difficulties by allowing the dispersion of multi-particulates directly into liquid or soft food, usually referred to as the “sprinkle” application. Moreover, encapsulating pellets doesn’t require any additional or specialized infrastructure, expertise, or technology since it employs a standard capsule filling process.Tablets are often favoured over capsules due to the lower production costs, but it is important to look at the bigger picture here. The total cost of ownership (TCO) for developing MUPS tablets extends beyond initial expense, requiring a high degree of precision that is achieved using not only specialised excipients and machinery but also expertise. These often-overlooked factors and hidden costs necessitate the importance of a comprehensive TCO analysis in making informed decisions about choosing the right drug delivery system.The questions we need to anwer include: is it worth developing a product loaded with so many risk factors? Why do ailing patients need to be exposed to unnecessary excipients with added costs? Why are simple available options no longer considered simple? Why are aesthetics more important than patients’ health? It is high time that we, the custodians of health, take cognizance and act accordingly for a better, healthier future.- Dr. Subhashis Chakraborty, Head, Global Product Management, ACG Capsules- Ananya Sen, Corporate Marketing, ACG GroupSource: https://www.pharmaindustrial-india.com/
Read more
ACG Joins List of WEF’s Global Lighthouse Network
ACG Joins List of WEF’s Global Lighthouse Network
ACG recently announced the inclusion of its capsule manufacturing facility in Pithampur, India, into the Global Lighthouse Network (GLN) by the World Economic Forum (WEF). WEF’s Global Lighthouse Network is a community of manufacturers which shows leadership in using Fourth Industrial Revolution technologies to transform factories, value chains and business models, for compelling financial and operational returns. The GLN has experienced exponential growth since its inception, expanding from 16 to 153 lighthouses. This initiative is a collaboration between WEF and Mckinsey & Company with independent panel of experts designating factories and value chains that join the GLN.The certification comes after audits of 25-plus use cases for the facility that have not only led to manufacturing of superior quality products but also, transformed operations creating new benchmarks for timely production, according to the company. ACG added that the company’s Pithampur factory exemplifies accelerated deployment of GenAI, addressing the evolving skill sets of employees in manufacturing through a Standard Operating Procedure (SOP) and policy interfacing with GenAI.“When ACG embarked on its journey to digital transformation, I recall how Industry 4.0, AI and ML were emerging concepts,” said Karan Singh, managing director of ACG Group. “The focus was directed toward deploying these technologies to enhance productivity and transform the way we operate; aiming to ultimately enhance accessibility to affordable medicines. With an ambitious and dedicated team, we forged a collective commitment to raise the bar of excellence in delivering high-quality capsules worldwide.”For more information, visit www.acg-world.com. Source: ACG Joins List of WEF’s Global Lighthouse Network
Read more
ACG joins coveted list of WEF's Global Lighthouse Network
ACG joins coveted list of WEF's Global Lighthouse Network
ACG, the world's largest integrated supplier and service provider to pharmaceutical industry celebrated the inclusion of its capsule manufacturing facility in Pithampur, India, into the esteemed Global Lighthouse Network (GLN) by the World Economic Forum. WEF's Global Lighthouse Network is a community of manufacturers which shows leadership in using Fourth Industrial Revolution technologies to transform factories, value chains and business models, for compelling financial and operational returns. Remarkably, the GLN has experienced exponential growth since its inception, expanding from 16 to 153 lighthouses. This initiative is a collaboration between WEF and Mckinsey & Company with independent panel of experts designating factories and value chains that join the GLN. The certification comes after robust audit of 25+ use cases for the facility, that have not only led to manufacturing of superior quality products but also, transformed operations creating new benchmarks for timely production. ACG's Pithampur factory exemplifies accelerated deployment of GenAI, addressing the evolving skill sets of employees in manufacturing through a remarkable Standard Operating Procedure (SOP) and policy interfacing with Gen AI. Commenting on the recognition, Karan Singh, Managing Director of ACG Group said, "When ACG embarked on its journey to digital transformation, I recall how Industry 4.0, AI and ML were emerging concepts. The focus was directed toward deploying these technologies to enhance productivity and transform the way we operate; aiming to ultimately enhance accessibility to affordable medicines. With an ambitious and dedicated team, we forged a collective commitment to raise the bar of excellence in delivering high quality capsules worldwide." He further added, "6 years into the journey, I am filled with pride as my team paves a path for leading advance manufacturing and securing a position in the World Economic Forum's prestigious community of Global Lighthouses. This certification is a testament to our commitment to excellence and creating new benchmarks of facilities that are operating on the leading edge of technological innovation. In time to come, we envision taking the learnings and success from this facility to scaling global operations collectively to make it better for our partners, customers, regulators and eventually the pharmaceutical ecosystem." Known for its many accolades, ACG's Pithampur factory had incorporated green features right during the design and layout stages marking a pioneer achievement as they were certified gold by LEED in 2014. Sharing valuable insights and expertise on the state-of-the-art technological advancements, Balajikasiram Sundararajan, Chief Digital Officer, ACG group added "Build the Future, ACG's enterprise-wide digital transformation program is based on four strategic pillars - transforming operations, building smart connected products, enhancing customer experience, and developing digital led business models. Under the ambit of build the future, ACG has been actively developing and implementing state-of-the-art solutions, powered by digital technologies ranging from Industrial IoT, machine learning, deep learning, generative AI, cloud computing, to digital twins, industrial robotics, and extended reality. He further added, "These solutions have helped us to better serve our global customer base by solving critical customer-centric business problems. This prestigious Global Lighthouse recognition from the World Economic Forum further inspires us to continually explore innovative ways of leveraging digital technologies to re-imagine our entire value chain starting from our suppliers to our customers" Kiva Allgood, Head, Centre for Advanced Manufacturing and Supply Chains, World Economic Forum, said, "The Global Lighthouse Network exemplifies the power of digital transformation. Lighthouses are pioneering a path to unprecedented global impact, strategically weaving innovation throughout their expansive network - sculpting both a sustainable future and an era of transformative and lasting change."Press release from the World Economic Forum can be accessed here https://www.weforum.org/press/2023/12/factories-of-the-future-show-how-to-apply-ai-to-benefit-people-planet-and-performance/ About the Global Lighthouse NetworkThe Global Lighthouse Network is a collaborative platform bringing together forward-thinking manufacturers leading the charge in adopting Fourth Industrial Revolution technologies. Leveraging innovations like artificial intelligence, 3D-printing, and big data analytics, Lighthouses drive efficiency, competitiveness, and transformative business models at scale, fostering economic growth while championing workforce augmentation, environmental protection and providing a collaborative learning journey for all-sized manufacturers globally. The Global Lighthouse Network is a World Economic Forum initiative co-founded with McKinsey & Company and counselled by an Advisory Board of industry leaders, including Contemporary Amperex Technology (CATL), Foxconn Industrial Internet, Henkel, Johnson & Johnson, Koc Holdings, Schneider Electric, and Siemens. Factories and value chains that join the network are designated by an independent panel of experts. About ACGFor over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies. As the world's most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards. Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world's greatest health challenges and make it better for everybody we serve.For more information, please contact the ACG media relations team: madhurima.chakraborty@acg-world.com (ADVERTORIAL DISCLAIMER: The above press release has been provided by PRNewswire. ANI will not be responsible in any way for the content of the same) Source: https://www.business-standard.com/content/press-releases-ani/acg-joins-coveted-list-of-wef-s-global-lighthouse-network-123121800955_1.html
Read more
ACG se junta à lista da Global Lighthouse Network do WEF
ACG se junta à lista da Global Lighthouse Network do WEF
A ACG, a maior fornecedora e prestadora de serviços para a indústria farmacêutica do mundo, comemora a inclusão de sua unidade de fabricação de cápsulas em Pithampur, na Índia, na reconhecida Global Lighthouse Network (GLN) pelo Fórum Econômico Mundial. A Global Lighthouse Network do WEF é uma comunidade de fabricantes que demonstra liderança na utilização de tecnologias da Quarta Revolução Industrial para transformar fábricas, cadeias de valor e modelos de negócios, obtendo grandes retornos financeiros e operacionais.A certificação surge após uma auditoria robusta de mais de 25 casos de uso para a instalação, que não só levaram à fabricação de produtos de qualidade superior, mas também transformaram as operações, criando novos padrões de referência para a produção. A fábrica da ACG em Pithampur exemplifica a implantação acelerada da GenAI, abordando os conjuntos de habilidades em evolução na fabricação por meio de um notável Procedimento Operacional Padrão (SOP) e interface de política com a Gen AI.Comentando sobre o reconhecimento, Karan Singh, Diretor Geral do Grupo ACG, disse: “Quando a ACG embarcou em sua jornada para a transformação digital, lembro-me de como a Indústria 4.0, IA e ML eram conceitos emergentes. O foco foi direcionado para a implantação dessas tecnologias para aumentar a produtividade e transformar a forma como operamos; com o objetivo de melhorar a acessibilidade a medicamentos. Com uma equipe ambiciosa e dedicada, estabelecemos um compromisso coletivo para elevar o padrão de excelência no fornecimento de cápsulas de alta qualidade em todo o mundo.”Ele ainda acrescentou: “6 anos de jornada, estou muito orgulhoso de ver a minha equipe abrindo caminho para liderar a fabricação avançada e garantir uma posição na prestigiada comunidade GLN do Fórum Econômico Mundial. Esta certificação é uma prova do nosso compromisso com a excelência e com a criação de novos padrões de referência em instalações que operam na vanguarda da inovação tecnológica. No futuro, pretendemos levar os aprendizados e o sucesso desta instalação para escalar as operações globais coletivamente e torná-la melhor para nossos parceiros, clientes, reguladores e também para o ecossistema farmacêutico.”A fábrica da ACG em Pithampur incorporou características ecológicas logo durante as fases de design e layout, marcando uma conquista pioneira, pois foi certificada ouro pelo LEED em 2014.Compartilhando informações valiosas e conhecimentos sobre os avanços tecnológicos de última geração, Balajikasiram Sundararajan, diretor digital do grupo ACG, acrescentou: “Construa o Futuro, o programa de transformação digital de toda a empresa da ACG é baseado em quatro pilares estratégicos - transformando operações, construindo produtos inteligentes conectados, melhorando a experiência do cliente e desenvolvendo modelos de negócios digitais. Pensando em construir o futuro, a ACG tem desenvolvido e implementado ativamente soluções de última geração, alimentadas por tecnologias digitais que vão desde IoT Industrial, aprendizagem automática, aprendizagem profunda, IA generativa, computação em nuvem, até gémeos digitais, indústria robótica e realidade estendida.O diretor reforça: “Essas soluções nos ajudaram a atender melhor nossa base global de clientes, resolvendo problemas críticos de negócios centrados no cliente. Este prestigiado reconhecimento Global Lighthouse do Fórum Económico Mundial inspira-nos ainda mais a explorar continuamente formas inovadoras de aproveitar as tecnologias digitais para estruturar toda a nossa cadeia de valor, desde os nossos fornecedores até aos nossos clientes”.Kiva Allgood, chefe do Centro de Fabricação Avançada e Cadeias de Fornecimento do Fórum Econômico Mundial disse: "A Global Lighthouse Network exemplifica o poder da transformação digital. Os faróis são pioneiros em um caminho para um impacto global sem precedentes, tecendo estrategicamente a inovação em toda a sua rede expansiva - esculpindo um futuro sustentável e uma era de mudanças transformadoras e duradouras.”O comunicado na íntegra do Fórum Econômico Mundial está diponivel no link: https://www.weforum.org/press/2023/12/factories-of-the-future-show-how-to-apply-ai-to-benefit-people%20-planeta-e-desempenho/Sobre a Global Lighthouse NewtworkA Global Lighthouse Network é uma plataforma colaborativa que reúne fabricantes com visão de futuro que lideram a adoção de tecnologias da Quarta Revolução Industrial. Aproveitando inovações como inteligência artificial, impressão 3D, os Lighthouses impulsionam a eficiência, a competitividade e modelos de negócios transformadores em escala, promovendo o crescimento econômico e ao mesmo tempo defendendo o aumento da força de trabalho, a proteção ambiental e proporcionando uma jornada de aprendizagem colaborativa para fabricantes de todos os tamanhos em todo o mundo.A Global Lighthouse Network é uma iniciativa do Fórum Econômico Mundial co-fundada com a McKinsey & Company e aconselhada por um Conselho Consultivo de líderes da indústria, incluindo Contemporary Amperex Technology (CATL), Foxconn Industrial Internet, Henkel, Johnson & Johnson, Koç Holdings, Schneider Electric e Siemens. As fábricas e cadeias de valor que integram a rede são designadas por um painel independente de especialistas. Sobre o Grupo ACGFundado em 1964 e operando no Brasil há 20 anos, o Grupo ACG é o único fornecedor mundial de soluções de fabricação integradas para a indústria farmacêutica. A empresa recebeu este ano o segundo lugar no Prêmio Sindusfarma de Qualidade, na categoria Fabricantes nacionais de matérias-primas. Conta com uma unidade fabril em Cotia (SP), a ACG Films & Foils, que oferece soluções em embalagens para as indústrias farmacêutica, alimentícia & FMCG (Fast-Moving Consumer Goods), e outra em Pouso Alegre (MG) focada na fabricação de cápsulas para as áreas farmacêutica e nutracêutica. Possui importantes certificações, como GMP, Halal e Kosher, se tornando um importante fabricante e distribuidor para todo o mercado doméstico, Latino-Americano, Norte-Americano e, recentemente, para a África. A ACG tem o compromisso com uma única meta: oferecer um portfólio completo de tecnologias e soluções integradas para a fabricação eficiente de sólidos orais. A multinacional está presente em mais de 100 países e tem mais de 4.500 funcionários em todo o mundo. https://www.acg-world.com/pt/EsclarecimentoA área Empresas em Foco publica notícias elaboradas e enviadas pelas empresas associadas ao Sindusfarma; seu conteúdo é de exclusiva responsabilidade das empresas e não reflete anuência nem posições ou opiniões da entidade.Source: ACG se junta à lista da Global Lighthouse Network do WEF
Read more
Richard Stedman appointed to CEO of ACG’s Engineering Division
ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceuticalindustries, has announced that Richard Stedman will rejoin the company as group chief executive officer of the Engineering Division. Throughout his career, Stedman has gained over 35 years of experience in the packaging, engineering and pharmaceutical manufacturing spheres, having led and transformed various businesses in multiple countries, including South Africa, Singapore, India, Australia and India.Stedman previously held the role of CEO of the Engineering Division at ACG from 2017 to 2021, and brings his wealth of engineering experience back to the role. Previously in this role, Stedman oversaw significant growth and achievement, including the successful completion of several high-profile projects. He was also a key player in expanding ACG’s presence in key global markets.Karan Singh, managing director at ACG, commented: “We are thrilled to have Richard back with us. Richard has a proven track record of success, and his leadership will be invaluable as we continue to grow and expand our operations.”Commenting on his reappointment, Stedman said: “I am excited to be returning to ACG Engineering as CEO. I have always had a deep respect for the company’s culture, values and commitment to excellence, and I look forward to working with the team to build on the success we have achieved in the past.”Commenting on his reappointment, Stedman said: “I am excited to be returning to ACG Engineering as CEO. I have always had a deep respect for the company’s culture, values and commitment to excellence, and I look forward to working with the team to build on the success we have achieved in the past.”Source: https://www.pharmafocus.com/
Read more
NBJ Nutrition Business Journal
NBJ Global Markets Overview - Q&A with Rafael Costa
Leading sales across North and South America for the mammoth contract manufacturer ACG, Rafael Costa keeps his feet on the ground in two hemispheres and a wide range of markets faced with a wide range of economic conditions and regulatory systems. We asked him for his quick thoughts on what he sees going on for supplements, looking south from the U.S.NBJ: Which of the South and Latin American markets are looking strongest right now? Costa: Brazil and Mexico are the two largest markets. Together, they represent 75% of vitamins and supplements sales in Latin America.NBJ: What are some of the categories driving growth in those markets? Costa: Vitamins, minerals and supplements, in general, are the predominant categories. In vitamins, historically the region has a predominance of vitamin C and calcium, the source being changed to calcium citrate malate. Most recently vitamin D, vitamin K2, zinc and magnesium have increased sales substantially. Within supplements, gastrointestinal (probiotics, fiber and enzymes), joint health (undenatured type II collagen, MSM and curcumin), sarcopenia (creatine), along with weight loss and multivitamins, drive most of the growth.NBJ: Which markets do you see as promising in the near-term future? Which channels are rising or fading? Costa: Brazil and Mexico are expected to keep growing. Also, Colombia and Chile are promising areas. In regard to sales channels, traditional retail is by far the largest sales channel and still growing, while online, MLM and direct selling are rising substantially. Compounding pharmacies also represent a big portion of the Brazilian market.NBJ: Where are the economic conditions impacting supplement sales? Costa: Political instability and economic conditions always have big impact on supplement sales across the Latin American market. Recent presidential elections have created an unsecure environment, which inhibits expenditure from population and investment from brands.NBJ: Do you see any changes in the MLM channel in the South American markets? Costa: For economic and regulatory reasons, in general, the MLM channel should continue to grow across Latin America, as it represents a unique opportunity to educate and better position supplements to most consumers versus other market channels.NBJ: What should U.S. companies understand about South America and what the future holds? Costa: In general, U.S. products and brands are well accepted across Latin America. A U.S. company interested in doing business in Latin America should understand the regulatory environment and legal requirements for that specific country. Each country has its own rules and what is feasible in Brazil could not be feasible in Mexico, for example. Finding a local partner, from a distribution to regulatory/ legal standpoint is key, to ensuring a successful product launch, and so you stay compliant with the local laws. Also, it is important to understand that most Latin American sales within the VMS segment come from pharmaceutical brands, as physician indication is still highly important for consumers’ decision making.
Read more
Virtual Inspections: Embracing the Digital Change
Virtual inspections must become a part of companies’ repertoires if they aim to maintain quality standards in their organisations.Digital tools and technologies are advancing rapidly – but how can pharma make the best use of them? One area of manufacturing that is ripe for enhancement via digital tools is product inspections.Udit K Singh, Chief Executive Officer at ACG Inspections explains.What historical challenges affect inspections today?Manual inspection methods increase the chance of rejecting an entire batch because of an anomaly in a single tablet or capsule from that batch. Whereas digital tools can identify defects at the individual product level – rejecting the defective products only. These tools also verify that the inspection has been carried out to the required parameters and that data, associated with the inspection, is stored.When inspecting products manually there is also the potential for defects to be missed. If these products reach the market, they can cause reputational damage to a brand, potentially resulting in lawsuits and revenue losses.Another historical challenge is that there hasn’t been any real-time qualification and analytics of manufacturing output. In my view, being able to provide assurance that each capsule or tablet has been qualified against the quality standards and a benchmark has been set by aggregators in this space is of crucial importance.What are the key benefits of digital inspections?The benefits of digital inspections are immense. Better throughput, improved quality outcomes and higher visibility are all possible to achieve when businesses choose to integrate digital inspections into their operations.Camera sensors use images captured to determine the chemistry, orientation, hardness and other product characteristics such as moisture. They work at high speed and on fast-moving production lines. Because they remove faulty products before they reach packaging the production performance is optimised. The operators just need to be trained to ensure the standard operating procedures (SOPs) are followed.Manual inspection is subjective. Humans require training and education and have limitations. For example, manual inspection makes it difficult to distinguish a “look-alike” product, minute variances in colour and other characteristics. Manual inspection is repetitive work, in often brightly lit conditions which means human performance will be varied and subject to fatigue – therefore the quality assurance cannot be validated.In the past, inspections at single points in a manufacturing plant, such as in-line and end-of-line product sampling were acceptable. Clearly, this type of check wouldn’t provide companies with a full picture. Digital inspections offer manufacturers the opportunity to create better data to support business decisions and the means to view the strengths and weaknesses of processes with improved transparency.In your view, are there any important limitations that must be considered?Technology evolution is happening at an enormously fast pace. As pharmaceutical manufacturing is governed by a set of compliance rules the adoption of technology takes time.You can’t adopt rapid changes in technology because the industry must go through phases of testing, adaptability, efficiency and productivity. By the time they are complete, five years may have already elapsed. Trying to keep up with the pace of technology development is becoming tough.Regulatory bodies and the pharmaceutical service industry need to collaborate regarding the regulations that become the baseline for technology development. This should allow for faster technology adoption for pharmaceutical companies.What are your thoughts on current penalties for facilities that don’t comply with regulations?Patient safety in drug manufacturing is the absolute top priority. There cannot be any compromise. Regulatory bodies are doing everything in their power to ensure that this is the case. If this is managed by imposing penalties, stopping production, recalling products or even questioning manufacturers they have the authority to decide what’s right to protect patients.However, the methods used to ensure that companies meet the regulation are at the discretion of the manufacturer. For inspections, they could adopt optical inspection using cameras or non-optical methods that use infrared ultrasound – to check the structure of drugs. Regardless of the approach they take, frequent checks and balances will always be their biggest responsibility. Quality checks at all stages of the process from raw material, batch mixing, API production, to the manufacture of the final finished tablet or capsule must be consistent. But the quality assurance process doesn’t stop there, companies must also invest time into evaluating blister packaging and bottles, label print quality, boxing, packing and shipping.Managing all these aspects of the manufacturing process can be quite intense, but technology can help in streamlining it. If companies choose to embrace the obvious benefits of digital inspections, they will certainly be able to better support patients worldwide.Source: https://pharmafile.com/news/virtual-inspections-embracing-the-digital-change/
Read more
Adding a new chapter to the history of capsule-based drug delivery
For more than 100 years, capsules have consisted of two pieces (a body and a cap). Nutritional or pharmaceutical ingredients are dosed into the body and the cap is then placed over the mouth and snapped shut. Now, however, next-generation technology is bringing a new dimension to this popular oral solid dosage form.Dr Kevin Robinson (KSR) recently caught up with Tobie Louw (TL), Vice President of Operations at Vantage Nutrition (An ACG Group Company), to discuss the market introduction of a new dietary supplement format called “Sidebysides”, brought about by the invention of the world’s first three-piece capsule, and to discover how they came to be.“The oral capsule has for more than 100 hundred years been the most effective and efficient way to bring the widest range of fixed-dose oral health solutions to market. There continues to be significant new investment in its ongoing evolution to assist with human health endeavours. This is the latest chapter in its rich history,” says Tobie.“Sidebysides” are the world’s first side by side separated oral dose health products for nutraceuticals and pharmaceuticals,” he says, “that have been created by the invention of a new three-piece capsule.”The third piece is the inventive introduction of a cup-shaped divider membrane inside a standard off-the-shelf capsule — made from the same material as the capsule — that acts as a divider inside the body of the capsule.""This enables wet and dry ingredients or incompatible actives to be housed side by side — together but separate in one product. “Sidebyside dietary supplements are rapidly gathering momentum since being launched in a vegetarian capsule format in 2020,” he adds.ComboCap, the technology-based start-up that invented and commercialised Sidebyside technology and products during the past 10 years, has developed and received 80 international patent awards for Sidebysides.The company designed, optimised and produced the unique Sidebyside technology and manufacturing process as well as the machines used to currently produce Sidebyside dietary supplements exclusively in their own world-first Sidebyside plant in New Jersey, US. ACG acquired ComboCap in early 2023.ACG is known for its enabling innovation and technology in the dietary supplement and pharmaceutical spaces.Discussing the manufacturing process, Tobie explains that a completely new type of encapsulation machine technology and process is used to produce Sidebyside products. “A Sidebyside machine takes an empty off-the-shelf hard capsule, removes the cap, doses the liquid and then inserts and seals the membrane into place. The cap is then replaced,” he says.“In the second stage of the process, the powder encapsulation takes place; the cap is removed, the powder dosed and the cap put back on — completing a Sidebyside product. This innovative technology is being extended to enable multiphase dosing on one single Sidebyside machine.”Groundbreaking technologyKey benefits for the greater life sciences industries include the fact that the three-piece Sidebyside form factor maximises the dose volumes on both sides of the membrane. It also enables customised dose sizes because the membrane position within the capsule is movable. Transparent capsules are used so that the contents of both chambers are fully visible.“The Sidebyside product format provides an ideal way to combine generally sensitive ingredients, such as probiotics, with other incompatible nutrients and actives,” adds Tobie.The dual-phase capsule-in-a-capsule has, of course, existed in the market for some time. In a cap-in-cap, a small capsule containing a powder dose is placed inside a larger one containing a liquid dose. This form factor results in the outer liquid capsule and dose being dissolved before the inner powder capsule and dose are. “With Sidebysides, the capsule shell of both chambers dissolve at the same time, enabling the ingredients to disperse and work together simultaneously; this delivers benefits such as the better absorption of key nutrients in the presence of oils.”The future rollout programme for Sidebyside products includes a number of features that cover the delayed release of the whole capsule and the release of the two independent chambers at different stages.“Delayed release is relevant because there is a significant market demand for health products that dissolve later in the digestive tract, or require a dual-stage instant beneficial effect followed by a gradual sustained one. An example of the latter is an oral health product that assists with falling asleep followed by staying asleep,” notes Tobie. KSR: What is the movable membrane and what is its function? TL: The membrane acts as a barrier between the two ingredients. It can be located in the optimum position, allowing the manufacturer to size the doses and the chambers accordingly — such as when one of the two ingredients requires a larger dose than the other.KSR: How do Sidebyside products differ from capsule-in-capsule products?TL: With Sidebysides, the separate ingredients operate together after ingestion; the chambers dissolve together. With cap-in-cap products, the separated ingredients dissolve sequentially. There are application needs for the sequential dissolution dynamic, especially when the inner chamber is required for late release.The Sidebyside product format and technology can however enable both parallel or sequential release, and can discharge either chamber ahead of the other depending on the need.Often, Sidebyside products can help to solve incompatibilities; examples include when ingredients haven’t previously been able to be combined or in the general case of needing to pair liquid and powder nutrients.By housing them with a dividing membrane, it’s possible to retain the identity and efficiency of the separated doses that may otherwise have been compromised if they had been combined and started reacting together sooner. This plays a role in enhanced product stability and shelf-life.When it comes to capsule-in-capsule products, the outer oil protects the inner capsule after ingestion and the powder is thereafter released for digestion. The oil helps to function as a delayed release solution. With Sidebysides, the use of clear capsules brings an added benefit in that a consumer has full side by side visibility of both separated ingredients in the capsule.This transparency can help to enhance patient trust ion the product and co-use buy-in and compliance. Product communication and marketing is also facilitated when references can be made to the separated contents.KSR: Can you expand on some of the enhanced combinations and what they can achieve? TL: Sidebyside products launched by brand companies to date have covered the following applications: general vitality, immunity, prenatal, woman’s health, men’s health, thyroid, sleep, calm, weight management and others.Select pharmaceutical Sidebyside applications are also being considered. One example is VASCEPA (icosapent ethyl) a pharmaceutical-grade fish oil. Published research by Amarin shows that VASCEPA DHA, when co-used with statins, brings patients a substantial enhancement in the benefits of the statin.Bringing a single two-in-one Sidebyside “VASVEPA-STAT” product to market would ensure co-use and give the combination solution in a more convenient single product format.KSR: Where next for this technology? TL: We are currently exploring a number of exciting controlled released options. This includes bringing single-stage, two-stage and triple-delayed release Sidebysides to market.Triple-delayed release Sidebysides can utilise a number of ingredient formats including liquids, powders and beadlets, whereby a mix of delayed-release beadlets is used to achieve the second and third stage release after the early stage release of the liquid dose.We are also progressing the development of beadlet-liquid and powder-powder and liquid-liquid Sidebyside health products. To date, no commercially available separated powder-powder oral health dose product exists in the market … and they have not been possible in existing capsule formats.In addition, we’re looking at developing the science behind exciting combinations such as prebiotic/probiotic Sidebysides in powder-powder form.By continuing to invest, extend, and bring to market the latest, most effective and efficient capsule technologies and innovative oral-dose health products, ACG continues to build its lead innovator status as a global top tier capsule company.Source: https://manufacturingchemist.com/
Read more
ACG acquires specialty packaging foils supplier
ACG strengthened its packaging solutions services by acquiring Technical Aluminum Foil Company.Capsules and packaging manufacturer ACG (Mumbai, India) has acquired specialty packaging foils supplier Technical Aluminum Foil Company (TAFC; Ajman, United Arab Emirates). ACG says this acquisition strengthens its comprehensive packaging solutions, especially in the Middle Eastern and African markets.TAFC’s aluminum and specialty packaging have high barrier properties and are used in both the pharmaceutical and food industries. The company also specializes in lacquering, lamination, printing, and slitting services.Source: https://www.nutritionaloutlook.com/
Read more
Ajit Singh
Ajit Singh
Ajit Singh earned his graduation degree from Cambridge University, UK, and post-graduation degree from Harvard Business School, USA. He currently resides in Mumbai, India, and travels widely to study pharmaceutical and allied industries.
Ajit is the Chairman of the ACG Group (formerly known as the Associated Capsules Group of Companies), which is headquartered in Mumbai. He has played a prominent role in the development of the pharmaceutical and allied industries in India and has served as an executive committee member of the Federation of Indian Chambers of Commerce & Industry (FICCI), a regional council member of the Confederation of Indian Industry (CII), Western Region, and other prominent pharmaceutical associations in India. He has also been conferred with prestigious awards for his contributions and thoughtful leadership to the pharmaceutical industry.
Ajit was a founder-member of the Young Presidents’ Organization – India Chapter and the first Indian to be invited to serve on its international board in the USA.
Jasjit Singh
Jasjit Singh
Along with his brother, Ajit, Jasjit started the Associated Capsules Group in Mumbai in 1962.
Jasjit has always been interested in technology – particularly that relating to machine design – and earned a degree in Mechanical Engineering from London University. He has dozens of patents to his credit, and under his leadership the ACG Group has received numerous global awards for technology, excellence and social welfare.
Jasjit has been actively involved with starting new Forums of the Young Presidents’ Organisation. He served as the Chairman of the Mumbai Chapter, and helped found the Kolkata Chapter before becoming a founding President of the World Presidents’ Organisation. Jasjit has also received the Vijay Ratna Award for leadership in Industry, and recognition from UNIDO for his contribution to the fields of pharmaceutical technology and environmental science.
Jasjit’s other interests include self-education, reading, music, collecting rare works of arts and helping young contemporary artists, cooking, and travelling to different parts of the world – especially with his family.
Karan Singh
Karan Singh
An organisational psychologist by education, Karan has transformed ACG from a modest Indian business into a world-renowned institution, revolutionising its vision and long-term strategy to ensure global growth. Karan has overseen ACG’s remarkable digital transformation, adopting breakthrough technologies that not only keep medicines safe, affordable, and accessible – but also vastly improve manufacturing and supply chains. Meanwhile, he has led a series of tuck-in acquisitions that ensure ACG pioneers continuously in terms of innovation and scale.
Passionate about converting ideas into growth opportunities, he supports entrepreneurial visions that solve real-world challenges. As an investor and mentor to more than 35 health-tech start-ups, guiding strategy, technology, expertise and networks, Karan seeks to consolidate the next generation of leadership – one that will secure better access and bridge availability across the global health industry.
Karan serves on the India Advisory Board for the India-Brazil Chamber of Commerce, is Co-Chair for FICCI LAC Regional Council, a key advisor to Nasscom, and an active contributor to the Global Lighthouse Network community of the World Economic Forum. Years of keen basketball-playing underpin his leadership, communication, and competitive spirit, and have brought about ACG-NBA Jump, a grassroots programme to give Indian basketballers a global platform.
Selwyn Noronha
CEO ACG CAPSULES
Selwyn Noronha
Nikhil Kulkarni
CEO ACG ENGINEERING
Nikhil Kulkarni
SR Shivshankar
CEO ACG PACKAGING MATERIALS
SR Shivshankar
Udit Singh
CEO ACG INSPECTION
Udit Singh
Sunil Jha
Chief Human Resource Officer
Sunil Jha
Werner Bongers
CEO SCITECH
Werner Bongers
Nitin Desai
Chief Commercial Officer
Nitin Desai
Parag Shah
Chief Financial Officer
Parag Shah
Shankar Gupta
Chief Sales Officer
Shankar Gupta
Balajikasiram Sundararajan
Chief Digital Officer
Balajikasiram Sundararajan
Alexander Robertson
Chief Marketing Officer
Alexander Robertson
Boilerplate
For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.
As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.
Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents.
Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve.
